IONS
Ionis Pharmaceuticals Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$55.96
-0.59 ▼ -1.04%
🌙 7월 27일 4:58 PM ET (한국 7/28 05:58)
$55.96
+0.00 +0.00%
아이오니스 파마슈티컬스(IONS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$9.2B
스몰캡
P/E
-
배당수익률
없음
52주 위치
34%
저점 +40% · 고점 -35%
애널리스트
적극 매수
C+
Fundamental health
vs. 방어주 대형주· based on 3 axes
수익성 산출 불가 (적자)
성장 Top 49%
밸류에이션 Top 42%
재무 안정 Top 66%
| Index | - | P/E | - | EPS (ttm) | -2.1 | Insider Own | 1.96% | Shs Outstand | 165.9M | Perf Week | 5.68% |
| Market Cap | 9.25B | Forward P/E | - | EPS next Y | 51.28% | Insider Trans | -27.98% | Shs Float | 162.0M | Perf Month | -28.57% |
| Enterprise Value | 9.88B | PEG | - | EPS next Q | -1.08 | Inst Own | 104.62% | Short Float | 12.37% | Perf Quarter | -23.62% |
| Income | -0.33B | P/S | 8.74 | EPS this Y | -53.3% | Inst Trans | 1.09% | Short Ratio | 7.32 | Perf Half Y | -30.3% |
| Sales | 1.06B | P/B | 18.89 | EPS next 5Y | - | ROA | -10.43% | Short Interest | 20.04M | Perf YTD | -29.26% |
| Book/sh | 2.96 | P/C | 4.68 | EPS past 3/5Y | -7.82% 5.62% | ROE | -67.54% | 52W High | -35.49% ($86.74) | Perf Year | 32.47% |
| Cash/sh | 11.96 | P/FCF | - | Sales past 3/5Y | 17.12% 5.29% | ROIC | -12.29% | 52W Low | 39.8% ($40.03) | Perf 3Y | 45.35% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 32.85% | Gross Margin | 96.73% | Volatility(W/M) | 5.05% 4.45% | Perf 5Y | 53.86% |
| Dividend TTM | - | EV/Sales | 9.34 | Sales Y/Y TTM | 47.4% | Oper. Margin | -33.35% | ATR (14) | 2.99 | Perf 10Y | 91.78% |
| Dividend Ex-Date | - | Quick Ratio | 4.09 | EPS Q/Q | 39.38% | Profit Margin | -30.87% | RSI (14) | 31.83 | Recom | 1.46 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.1 | Sales Q/Q | 86.98% | SMA20 | -14.02% ($65.08) | Beta | 0.43 | Target Price | $92.05 |
| Payout | - | Debt/Eq | 5.31 | Earnings | 2026/7/29 | SMA50 | -21.28% ($71.09) | Rel Volume | 0.93 | Prev Close | $56.55 |
| Employees | 1402 | LT Debt/Eq | 4.41 | EPS/Sales Surpr. | 36.11% 25.79% | SMA200 | -25.88% ($75.5) | Avg Volume(3M) | 2.74M | Price | $55.96 |
| IPO | 1991/5/17 | Option/Short | Yes/Yes | Trades | 21469 | Volume | 2,549,757 | Change | -1.04% |
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12
25.3
25.6
25.9
25.12
26.3
Revenue Net income 최근 분기: 매출 $246M (YoY +87%) · 순이익 $-93M (YoY +37%)
Ionis Pharmaceuticals Inc (IONS) Investment Analysis
What kind of company is Ionis Pharmaceuticals Inc?
아이오니스 파마슈티컬스(IONS) 방어주
Healthcare · Biotechnology
#995 by Market Cap — Mid-Cap
This U.S. biopharmaceutical company is a leading player in antisense drug development, creating treatments for rare and chronic diseases based on antisense technology that regulates protein production at the genetic level. The company is currently transitioning toward the commercialization of its own drug products.
Learn more about Ionis Pharmaceuticals Inc →Market Cap
$9.2B
Approx. KRW 12.7 trillion
⚖️ 3% of Samsung Electronics
Market Cap Rank995
Employees1,402people
IPO1991/05/17
Current Price$55.96 ≈ 76,665원
Key Events
⏰ Upcoming events
🔔 Earnings release D-2
7월 29일 (수) · 장 시작 전
예상 EPS $-1.08
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 4월 29일 (수) · 장 시작 전 EPS +36.1% 매출 +25.8%
🔔 Earnings release 2026년 2월 25일 (수) · 장 시작 전
Is it profitable?
Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-33.4%
✓ 적자
Net Margin
Share of revenue left after taxes and interest are paid
-30.9%
✓ 적자
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
96.7%
✓ 우수
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-67.5%
✓ 적자
ROA
Annual earnings relative to total company assets
-10.4%
✓ 적자
ROIC
Return generated per dollar invested in the business
-12.3%
✓ 적자
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
5.31
✓ Danger level
Current Ratio
Liquid assets available to cover liabilities due within a year
4.10
✓ 평균
Quick Ratio
Liquid assets excluding inventory, available for immediate use
4.09
✓ 양호
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$92.05
현재가 대비 +64.5%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+51.3%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+33.2%
평균 서프라이즈
2026.04.29
상회
실적 $-0.30 · 예상 $-0.78 +60.9%
2026.02.25
상회
실적 $-1.15 · 예상 $-1.22 +5.6%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.
Is it growing?
Average Growth
Mid-range within the industry
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-53.3%
매우 부진
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+51.3%
우수
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-7.8%
부진
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+5.6%
양호
Past 5-Year Revenue
How much revenue grew over the past 5 years
+5.3%
평균
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+87.0%
우수
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Underperformed the market by 14%p over 5 years
IONS +53.9% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-14.5%p
behind the market
vs Health Care (XLV)
+29.4%p
ahead of the sector average
1-year basis
vs S&P 500
+16.5%p
ahead of the market
vs Health Care (XLV)
+12.8%p
ahead of the sector average
Rank among peers
5-year return Upper-Mid (49%) Based on 24 peers
1-year return Lower-Mid (lower 43%) Based on 24 peers
Current position within 52-week range
Low (-39.8%p) High (-35.5%p)
Current price is 39.8% above the 52-week low and 35.5% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-38.8%
Annualized volatility
51.2%
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current diagnosis · 2026-07-27
Downtrend zone
Current price $55.96 below the midline ($65.08). Normal downward flow. Below the Ichimoku cloud (bearish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
Current diagnosis · 2026-07-27
Bearish momentum holding
MACD -5.682 < Signal -5.122 in negative zone + Hist negative (-0.560). Weakness in progress.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
Current diagnosis · 2026-07-27
Bearish zone
RSI 31.8 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 16.2.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
In line with the industry average
Cheap on Vs. Sales, In line with peers on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Assets Mid-range
Vs. Sales Cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
18.89x
✓ Fair
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
8.74x
✓ Cheap
Analyst target price (reference)
$92.05 vs. current price +64.5%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 대형주
Who owns it?
Ownership flow shows some pressure
Insider net selling -28.0% · Institutional net buying +1.1% · Short interest elevated 12.4% · Short interest up +2.9pp over last 90d
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
-28.0%
Insiders large net selling
🏦 Institutions (funds & investors)
+1.1%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 104.6%
Institution-led, stable structure
🧑💼 Insiders 2.0%
Typical level
👤 Retail investors (estimated) 0.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
12.4%
Somewhat high
Past 90 days 📈 +2.9%p increase
Short interest days to cover
7.3 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 165.9M주
Float (tradable shares) 162.0M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
ETFs holding IONS
ETFs with the highest weightings · 10 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
This company does not pay a dividend
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| IONS This Stock | $9.2B | - | 18.9 ▼ | -67.54% ▼ | - | -1.0% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
Derivative ETFs for IONS
Leveraged, inverse, and covered call ETFs based on the underlying asset
21 derivative ETFs based on IONS (Leverage 8 · Inverse 5 · Covered Call 8)
These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.
ℹ️ What is a Derivative ETF?
These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.
⚠️ Caution: Long-Term Holding
Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.
Leverage 8 ETFs that move 2-3x with IONS (high volatility)
XQQI
NEOS Boosted Nasdaq-100 High Income ETF
-0.26%
$245M
XBAP
Innovator U.S. Equity Accelerated 9 Buffer ETF - April
+0.13%
$131M
XBCI
NEOS Boosted Bitcoin High Income ETF
+1.38%
$104M
XBJA
Innovator U.S. Equity Accelerated 9 Buffer ETF - January
+0.16%
$88M
XSPI
NEOS Boosted S&P 500 High Income ETF
+0.23%
$79M
SEMY
GraniteShares YieldBOOST Semiconductor ETF
-0.49%
$78M
XBJL
Innovator U.S. Equity Accelerated 9 Buffer ETF - July
+0.13%
$74M
XDSQ
Innovator U.S. Equity Accelerated ETF - Quarterly
+0.09%
$69M
Inverse 5 Profits when IONS falls (downside bet)
WNTR
YieldMax MSTR Short Option Income Strategy ETF
-5.13%
$80M
FIAT
YieldMax Short COIN Option Income Strategy ETF
-4.69%
$36M
CRSH
YieldMax Short TSLA Option Income Strategy ETF
+0.99%
$18M
YQQQ
YieldMax Short N100 Option Income Strategy ETF
+0.34%
$15M
DIPS
YieldMax Short NVDA Option Income Strategy ETF
+3.69%
$8M
Covered Call & Options 8 A strategy that generates monthly dividend income through covered calls
DFAC
Dimensional U.S. Core Equity 2 ETF
+0.11%
$47.5B
JEPI
JPMorgan Equity Premium Income ETF
+0.51%
$45.3B
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
-0.38%
$39.2B
DFUS
Dimensional U.S. Equity Market ETF
+0.06%
$20.6B
DFAS
Dimensional U.S. Small Cap ETF
+0.45%
$15.2B
QQQI
NEOS Nasdaq 100 High Income ETF
-0.28%
$13.3B
BOXX
Alpha Architect 1-3 Month Box ETF
+0.03%
$13.2B
SPYI
NEOS S&P 500 High Income ETF
+0.04%
$10.8B
FAQ
What kind of company is 아이오니스 파마슈티컬스(IONS)?
아이오니스 파마슈티컬스(IONS) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IONS?
The market cap of IONS is approximately $9.2B, ranking 995 within its sector.
What is the 52-week high and low for IONS?
IONS has recorded a 52-week high of $86.74 and a low of $40.03.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.